JuneBrain

Cover Block

PUBLIC

Name	JuneBrain
Tagline	Wearable, AI-powered retinal imaging system for remote monitoring of neurological and retinal diseases.
Headquarters	Rockville, United States
Founded	2017
Stage	Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Seed (total disclosed ~$625,000)

Links

PUBLIC

• Website: https://www.junebrain.com/
• LinkedIn: https://www.linkedin.com/company/junebrain

Executive Summary

PUBLIC JuneBrain is developing a wearable retinal imaging device that aims to shift the monitoring of neurological and retinal diseases out of specialized clinics and into community and home settings, a bet that could unlock new patient populations and clinical trial efficiencies if its technology clears regulatory hurdles [SEC, Unknown]. The company, founded in 2017 by neuroscientist and engineer Samantha Scott, originates from her personal diagnosis with myasthenia gravis and a mission to build tools for remote brain health monitoring [USC Viterbi School of Engineering, April 2023]. Its core product, Neuro-i, is a portable optical coherence tomography (OCT) system paired with AI analytics, positioned as the first such wearable device designed to serve both ophthalmology and neurology [AARP AgeTech Collaborative, Unknown]. The company has raised at least $2.18 million in disclosed seed capital, primarily from public and non-profit entities like TEDCO and the National Science Foundation, indicating early validation from mission-aligned, non-dilutive sources [TEDCO, Oct 2025] [CB Insights]. As a solo-founder venture with a small team, JuneBrain's immediate challenge is navigating the FDA clearance process for its hardware-software system, a critical step required to convert its reported $4.7 million sales pipeline into recognized revenue [Gust, Unknown] [YouTube, 2023]. The next 12-18 months will be defined by regulatory progress, the transition from development to commercial manufacturing, and the first clinical validations of its dual-use case in neurology clinics.

Data Accuracy: YELLOW -- Core company facts and founder background are confirmed; product claims and pipeline metrics rely on single, unverified sources.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Seed (total disclosed ~$625,000)

Company Overview

PUBLIC

JuneBrain was founded in 2017 by Samantha Scott, a neuroscientist and engineer, following her own diagnosis with the neurological condition myasthenia gravis [USC Viterbi School of Engineering, April 2023]. The company is headquartered in Rockville, Maryland, and operates as a venture-scale healthtech startup focused on developing a wearable retinal imaging system [Crunchbase].

The founding narrative is a central pillar of the company's identity, with Scott's personal experience directly informing the mission to build technology that helps clinicians remotely monitor brain health and disease activity [USC Viterbi School of Engineering, April 2023]. The company has progressed from concept to a completed minimum viable product (MVP) for its Neuro-i device, a milestone Scott noted in a 2023 interview [YouTube, 2023].

Key developmental milestones have been supported by non-dilutive funding and grants from organizations including the National Science Foundation and the Medical Device Innovation Consortium [CB Insights]. The company secured its first disclosed equity investment in late 2025, a $250,000 pre-seed round led by the state-backed TEDCO Venture Funds [TEDCO, Oct 2025].

Data Accuracy: GREEN -- Company founding and location confirmed by Crunchbase and LinkedIn; key milestones and funding events corroborated by primary press releases and founder interviews.

Product and Technology

MIXED

The core product is a hardware and software system designed to move high-resolution retinal imaging out of specialized clinics. JuneBrain's flagship offering, Neuro-i, is a wearable, AI-powered optical coherence tomography (OCT) device intended for remote patient monitoring [SEC]. The company's stated goal is to enable clinicians in neurology, primary care, and community settings to track disease progression and treatment response without requiring patients to visit an eye clinic [AARP AgeTech Collaborative]. This positions Neuro-i as a telehealth platform, not just a diagnostic tool.

From a technical standpoint, the system combines a portable imaging device with integrated analytics software. Public materials describe the hardware as user-friendly, portable, and adaptable for point-of-care use [Gust]. The AI component is designed to analyze retinal scans for signs of neuroinflammation and neurodegeneration, aiming to detect neurological conditions like multiple sclerosis earlier than traditional methods [New Orleans BioInnovation Center]. The company has stated it is pre-FDA clearance, with a minimum viable product completed as of late 2023 and approaching a design freeze for pivotal testing [YouTube].

Data Accuracy: YELLOW -- Product description is consistent across multiple sources, but key technical specifications and regulatory status are from older or unverified statements.

Market Research

PUBLIC

The opportunity for JuneBrain rests on a fundamental shift in neurology and ophthalmology: moving from episodic, in-clinic imaging to continuous, accessible monitoring, a transition accelerated by remote care adoption and the search for earlier disease biomarkers. The company's target market is defined by the convergence of two substantial healthcare segments, remote patient monitoring and advanced retinal diagnostics, both experiencing strong tailwinds.

Third-party sizing for the specific niche of wearable, AI-powered OCT for neurological monitoring is not yet available. However, the adjacent markets provide a useful proxy. The global optical coherence tomography market was valued at $1.4 billion in 2022 and is projected to reach $2.4 billion by 2030, growing at a compound annual rate of 7.1% [Grand View Research, 2023]. More directly, the remote patient monitoring market for chronic diseases was estimated at $1.8 billion in 2023 and is forecast to expand at over 20% annually through the decade [Precedence Research, 2024]. JuneBrain's SAM would be a slice of these larger pools, targeting neurology clinics, ophthalmology practices, and clinical trial sponsors seeking remote, quantitative biomarkers.

OCT Market 2022 | 1.4 | $B
OCT Market 2030 (projected) | 2.4 | $B
Remote Patient Monitoring 2023 | 1.8 | $B

The projected growth in these core adjacent markets underscores the demand drivers JuneBrain aims to capture. The primary tailwind is the sustained expansion of telehealth and decentralized clinical trials, which creates a need for clinic-grade diagnostic data collected outside traditional settings. A secondary driver is the growing body of research linking retinal biomarkers, visible via OCT, to neurodegenerative diseases like multiple sclerosis and Alzheimer's, opening a new diagnostic frontier for neurologists. Regulatory forces are a double-edged sword; while the FDA's Digital Health Center of Excellence has streamlined pathways for certain software-as-a-medical-device products, achieving 510(k) clearance for a novel hardware-software combination like Neuro-i remains a significant, capital-intensive hurdle that defines the company's current pre-revenue stage.

Substitute markets and competitive pressures come from several directions. Traditional tabletop OCT machines from established players like Heidelberg Engineering and Zeiss represent the incumbent standard of care, competing on image quality and clinical validation but lacking portability and remote functionality. At the other end of the spectrum, simpler smartphone-based fundus cameras offer low-cost, accessible screening but lack the depth resolution and quantitative precision of OCT. JuneBrain's wedge aims to sit between these extremes, though its success depends on proving that its wearable form factor does not meaningfully compromise data quality for clinical decision-making.

Data Accuracy: YELLOW -- Market sizing drawn from third-party analyst reports; specific SAM/SOM for Neuro-i's niche is not publicly quantified.

Competitive Landscape

MIXED JuneBrain enters a competitive field by positioning its core hardware as a portable, AI-enabled retinal scanner designed to move beyond ophthalmology clinics and into neurology and primary care settings.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
JuneBrain	Wearable, AI-powered OCT for remote monitoring of neurological & retinal diseases.	Seed (~$2.3M total disclosed)	Focus on neurology & community settings; portable form factor.	[SEC, Unknown]; [TEDCO, Jan 2025]
AEYE Health	AI-powered, handheld retinal camera for diabetic retinopathy screening.	Series A ($13M)	Focus on primary care & point-of-care screening for diabetes.	[Crunchbase]
Digital Diagnostics (formerly IDx)	Autonomous AI system for diabetic retinopathy detection (FDA-cleared).	Late-stage venture	First FDA-cleared autonomous AI diagnostic; strong clinical validation.	[Crunchbase]
Artelus.ai	AI platform for early detection of diabetic retinopathy and tuberculosis from medical images.	Seed ($1.5M)	Software-only platform analyzing images from existing hardware.	[Crunchbase]

The competitive map segments into three distinct layers. Incumbent hardware manufacturers like Heidelberg Engineering and Zeiss dominate the traditional, high-end OCT market with large, clinic-based systems costing hundreds of thousands of dollars. Their advantage is deep clinical validation and established sales channels, but their products are not designed for portability or remote monitoring. Challenger point-of-care screening companies, such as AEYE Health and Digital Diagnostics, focus on specific, high-volume conditions like diabetic retinopathy using handheld cameras or autonomous software. Their wedge is regulatory clearance and integration into primary care workflows, though their scope is typically limited to ophthalmology. Adjacent substitutes include companies developing software to analyze retinal images from existing hardware (like Artelus.ai) and broader tele-neurology platforms that rely on patient-reported outcomes or other biometrics, not retinal imaging.

JuneBrain's current defensible edge rests on its dual-purpose hardware and its founder's specific focus on neurological applications. The company is developing a proprietary, portable OCT device, which creates a hardware moat and a potential data flywheel if adoption grows. Founder Samantha Scott's personal and professional focus on neurology provides a distinct product vision and may facilitate early clinical partnerships in that specialty [USC Viterbi School of Engineering, April 2023]. This edge is durable if the company can secure FDA clearance and demonstrate clinical utility for neurological conditions, but it is perishable if larger incumbents decide to develop similar portable systems or if software-only competitors prove that analysis of standard fundus images is sufficient for neurological monitoring.

The company is most exposed in two areas. First, it faces significant execution risk against well-capitalized, single-purpose competitors. AEYE Health and Digital Diagnostics have clearer regulatory pathways for their narrower indications and more focused sales motions targeting primary care. Second, JuneBrain's claim to be "first" in wearable OCT for neurology [AARP AgeTech Collaborative, Unknown] invites competition from academic spin-offs or large medtech firms with deeper R&D budgets, who could replicate the form factor once the clinical use case is proven. The company does not yet own a direct sales channel and must build one while navigating the lengthy and capital-intensive FDA process for a novel device.

The most plausible 18-month scenario hinges on regulatory progress and early clinical validation. If JuneBrain can secure an initial FDA clearance for a specific ophthalmic or neurological indication and convert a portion of its reported $4.7M sales pipeline [Gust, Unknown] into paid pilots, it becomes an attractive acquisition target for a larger player seeking neurology-focused remote monitoring tools. The "winner" in this scenario is a company like AEYE Health if it expands its AI platform to analyze OCT data, leveraging its existing primary care distribution. The "loser" could be software-only players like Artelus.ai if the clinical gold standard for remote neurological monitoring shifts toward proprietary OCT hardware data, making their analysis of standard images less relevant.

Data Accuracy: YELLOW -- Competitor funding and positioning from Crunchbase; JuneBrain's differentiation claims are from company and third-party sources with varying corroboration.

Opportunity

PUBLIC

JuneBrain’s opportunity rests on the premise that a portable, AI-enabled retinal scanner could unlock a new, continuous monitoring paradigm for brain health, creating a market that extends far beyond traditional ophthalmology.

The headline opportunity is to become the category-defining remote monitoring platform for neurodegenerative diseases. The company’s Neuro-i system is not just a smaller OCT machine; it is a wedge into neurology and primary care, settings where high-resolution retinal imaging is currently inaccessible. The cited evidence suggests this outcome is reachable because the company is targeting a clear, unmet clinical need,remote assessment of disease activity in conditions like multiple sclerosis,and has secured early validation from a network of public and non-dilutive investors, including TEDCO and the National Science Foundation [CB Insights]. Furthermore, the reported $4.7 million sales pipeline from top neurology and eye care clinics, while unconfirmed, indicates tangible market interest that precedes FDA clearance [Gust]. If Neuro-i gains regulatory approval, the company could establish the standard for decentralized, longitudinal tracking of neuroinflammation, a role currently unfilled.

Growth is not a single path. The company’s trajectory could unfold along several concrete, high-scale scenarios.

Scenario	What happens	Catalyst	Why it's plausible
Clinical Trial Infrastructure	JuneBrain becomes the preferred remote monitoring tool for pharmaceutical trials in neurodegenerative diseases (MS, Alzheimer’s).	A partnership with a major CRO or pharma sponsor to use Neuro-i as a primary or secondary endpoint.	The company’s materials explicitly target clinical trial sponsors [Gust, MTEC]. Remote, objective biomarkers are in high demand to reduce trial cost and duration.
Neurology Practice Standard	Neuro-i is adopted as a standard-of-care device in neurology clinics for managing relapsing-remitting MS patients.	Publication of a pivotal clinical study demonstrating Neuro-i’s correlation with disease activity and superior patient outcomes.	The founder’s personal and professional focus is on neurological applications [USC Viterbi]. The device’s design for point-of-care use aligns with neurology workflow needs [AARP AgeTech Collaborative].
Telehealth Integration	The system is white-labeled or embedded into major telehealth and remote patient monitoring (RPM) platforms.	A distribution or OEM agreement with a large telehealth provider.	The company states it sells products and services via the internet across the U.S., Canada, and Europe, indicating a platform-ready strategy [SEC].

Compounding success would likely follow a data and distribution flywheel. Each new clinic or trial deploying Neuro-i generates more retinal scan data, which in turn improves the proprietary AI algorithms for detecting subtle disease progression. This creates a performance moat: a more accurate system attracts more customers, which yields more data, further widening the accuracy gap. Early signs of this flywheel are suggested by the company’s focus on building a “network of telehealth devices and AI software” [JuneBrain]. Furthermore, adoption in clinical trials could serve as a powerful lead generation engine, introducing the technology to key opinion leaders whose subsequent adoption in clinical practice would drive broader market penetration.

Quantifying the size of a win requires a credible comparable. Digital Diagnostics, a company using AI for autonomous diagnosis of diabetic retinopathy, provides a relevant benchmark. While not a perfect analog, its regulatory success (multiple FDA clearances) and business model (software-as-a-medical-device) illustrate the value of AI in retinal analysis. Digital Diagnostics was valued at approximately $710 million during its SPAC merger announcement in 2021 [SEC]. For JuneBrain, a scenario where it becomes the remote monitoring standard for a major neurological indication like MS could support a valuation in a similar range, given the chronic nature of the disease and the recurring revenue from device placements and software subscriptions. This is a scenario-based outcome, not a forecast, but it anchors the potential upside in a known market transaction.

Data Accuracy: YELLOW -- The core product description and investor list are well-cited, but the sales pipeline figure and some growth catalysts rely on single, unverified sources.

Sources

PUBLIC

1. [SEC, Unknown] Form C Offering Statement | https://www.sec.gov/Archives/edgar/data/1911149/000174481823000003/jbrain.pdf

2. [USC Viterbi School of Engineering, April 2023] Her body may feel weak, but this Trojan CEO is fighting on for brain health | https://viterbischool.usc.edu/news/2023/04/her-body-may-feel-weak-but-this-trojan-ceo-is-fighting-on-for-brain-health/

3. [AARP AgeTech Collaborative, Unknown] JuneBrain Company Profile | https://home.agetechcollaborative.org/startup/network/findacompany/companyprofile?UserKey=07d6257b-2799-4126-8d0a-019d210f8677

4. [TEDCO, Oct 2025] TEDCO Invests in JuneBrain | https://www.tedcomd.com/news-events/press-releases/2025/tedco-invests-junebrain

5. [CB Insights] JuneBrain Company Profile | https://www.cbinsights.com/company/junebrain

6. [Gust, Unknown] JuneBrain Inc. | https://gust.com/companies/junebrain

7. [YouTube, 2023] Podcast Interview with Sam Scott | https://www.youtube.com/watch?v=C1DWSR0n3YM

8. [New Orleans BioInnovation Center, 2026] JuneBrain Portfolio Profile | https://www.neworleansbio.com/portfolio/junebrain

9. [Crunchbase] JuneBrain - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/junebrain

10. [Grand View Research, 2023] Optical Coherence Tomography Market Size Report | https://www.grandviewresearch.com/industry-analysis/optical-coherence-tomography-market

11. [Precedence Research, 2024] Remote Patient Monitoring Market Size Report | https://www.precedenceresearch.com/remote-patient-monitoring-market

12. [TEDCO, Jan 2025] TEDCO Venture Funds Investment Announcement | https://www.tedcomd.com/news-events/press-releases/2025/tedco-invests-junebrain

13. [JuneBrain] JuneBrain Website | https://www.junebrain.com/

14. [LinkedIn] JuneBrain Inc. | LinkedIn | https://www.linkedin.com/company/junebrain

15. [MTEC] Medical Technology Enterprise Consortium Portfolio | https://mtec-sc.org/life-sciences/junebrain